|
|
The HIV Pipeline - A Complete OverviewPublished by: Datamonitor Published: Jul. 5, 2002 - 65 Pages Table of ContentsACTION POINTS Outline of the brief Four key things you need to know about the HIV Market HIV PIPELINE ANALYSIS BY CLASS NNRTI Product Pipeline Calanolide A AG 1549 TMC125 NRTI Product Pipeline Coactinon Coviracil Ziagen / Epivir Combination Amdoxovir MIV-310 ACH-126,443 PI Product Pipeline Zrivada Amprenavir pro-drug PNU-140690 TMC114 DMP-450 Entry Inhibitor Product Pipeline T-20 Viraldon PRO-542 S1360 T-1249 AMD3100 Immunotherapeutic Product Pipeline Proleukin Reticulose WF10 HE2000 Biologics Product Pipeline Remune AIDSVAX B/E & M/E MVA-BN HIV NEF L.E.A.P.S. with HGP-30 VIR201 Other Products in Pipeline Ampligen Memantine COMPANY ANALYSIS HIV Pipeline Class Composition Diversity of Pipeline Analyst Insight APPENDIX R&D research methodology Hypothesis formulation Hypothesis testing Data verification and quality control References Bibliography Relevant links Datamonitor's Infectious Disease Business Unit Contacts and Future Readings AbstractIntroduction: Analysis of the late and early stage HIV pipeline, including antiretrovirals, vaccines and immunotherapies, and identifying licensing opportunities across geographical markets and differentiated therapeutic sectors. Scope of this Report: * Class by class analysis of the 101 pipeline candidates currently in development for the treatment of HIV * Drug classes include NNRTIs, NRTIs, Protease Inhibitors, Entry Inhibitors, Immunotherapeutics and Biologics * Interpretation of clinical and commercial aspects of the 31 candidates in phase II and III trials * Comparative overview of the characteristics of the HIV pipeline by class composition, and company type * Strategic insight into the future shape of the market, and key considerations for players at all levels from discovery to marketing specialists. Report Highlights: HIV management is due to undergo a major shift with the imminent introduction of new classes of therapeutic products. While the majority of pipeline candidates appear to be intended for complementary use with conventional therapeutics, some may have the potential to force older products out of the market. Differentiation, forced by a plateau in advance in meeting unmet need, will attract new players from distinct sectors to compete in the HIV market, forcing conventional market leaders to reappraise both their position in the market, and approach to its future domination. Whilst some new market entrants may be able to drive their own market penetration, the majority will require the market presence of more established players to achieve market entry. Tactical collaboration will prove central to market growth. Key reasons to Buy this Report: * Features, benefits, strengths and weaknesses of all major products set to enter the HIV market and a reference to all developmental compounds * Assess the impact of novel class entry on current HIV therapeutics, and the flexibility of existing classes to counter this potential revolution * Appraise the strategies employed by market leaders to counter the imminent arrival of numerous new market entrants * Identify the tactics new market entrants will employ to maximize impact on a market currently dominated by a small number of strong competitors * Identify potential candidates for licensing through an independent analysis of the positioning of pipeline candidates and their developers.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||